CHICAGO – In a phase III clinical trial, a new targeted medicine, taselisib, combined with standard hormone therapy fulvestrant (Faslodex®), halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%. Taselisib targets a common genetic abnormality in breast cancer – PIK3CA gene mutation – and is the first and most potent treatment in a relatively new class of PI3K inhibitors, according to the authors.
CHICAGO – An analysis of health claims data from two demographically similar regions on either side of the U.S. and Canada border shows that a common treatment for advanced colorectal cancer costs twice as much in Western Washington State (WW) than in British Columbia (BC) -- $12,345 vs. $6,195 monthly per patient. Despite the higher cost, the patients on the U.S. side of the border are not living longer than those on the Canadian side.
CHICAGO – In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Zytiga®) was greater and longer lasting in black men than in white men. Black men were more likely to have a decline in prostate-serum antigen (PSA) -- a sign of prostate cancer response -- and had a 5-month longer median time to PSA worsening than white men (16.6 vs. 11.5 months).
CHICAGO – An analysis of pooled data from nine randomized phase III trials of more than 8,000 men with advanced prostate cancer who received chemotherapy shows chances of survival are as good for black men as white men. The median survival was the same in black men and white men overall (21 months), but black men had a 19% lower risk for death than white men when researchers adjusted for various important risk factors that affect survival.
CHICAGO – An analysis of cancer registry data from a California hospital system shows that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs. 46%) and radiation (60% vs. 70%) compared to men. Controlling for factors such as age and serious medical conditions, a mathematical model also shows that the ratio of cancer to non-cancer mortality was two times higher for women than the ratio for men. When taken collectively, the findings raise the possibility women with head and neck cancer may be undertreated. The authors explain that there are some confounding factors, so further prospective investigation is necessary to fully address this possibility.
CHICAGO – A federally funded randomized study demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication.